These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 19815247)

  • 21. Immunogenicity of HIV-1 envelope glycoprotein oligomers.
    Forsell MN; Schief WR; Wyatt RT
    Curr Opin HIV AIDS; 2009 Sep; 4(5):380-7. PubMed ID: 20048701
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein.
    Du SX; Idiart RJ; Mariano EB; Chen H; Jiang P; Xu L; Ostrow KM; Wrin T; Phung P; Binley JM; Petropoulos CJ; Ballantyne JA; Whalen RG
    Virology; 2009 Dec; 395(1):33-44. PubMed ID: 19815247
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunization of rabbits with highly purified, soluble, trimeric human immunodeficiency virus type 1 envelope glycoprotein induces a vigorous B cell response and broadly cross-reactive neutralization.
    Quinnan GV; Onabajo O; Zhang P; Yan L; Mattapallil JJ; Zhang Z; Dong M; Lu M; Montefiori D; LaBranche C; Broder CC
    PLoS One; 2014; 9(5):e98060. PubMed ID: 24846288
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein.
    Klasse PJ; Depetris RS; Pejchal R; Julien JP; Khayat R; Lee JH; Marozsan AJ; Cupo A; Cocco N; Korzun J; Yasmeen A; Ward AB; Wilson IA; Sanders RW; Moore JP
    J Virol; 2013 Sep; 87(17):9873-85. PubMed ID: 23824824
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Uncleaved and Mature Human Immunodeficiency Virus Membrane Envelope Glycoprotein Trimers.
    Castillo-Menendez LR; Witt K; Espy N; Princiotto A; Madani N; Pacheco B; Finzi A; Sodroski J
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29618643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conformational States of a Soluble, Uncleaved HIV-1 Envelope Trimer.
    Liu Y; Pan J; Cai Y; Grigorieff N; Harrison SC; Chen B
    J Virol; 2017 May; 91(10):. PubMed ID: 28250125
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Specific amino acids in the N-terminus of the gp41 ectodomain contribute to the stabilization of a soluble, cleaved gp140 envelope glycoprotein from human immunodeficiency virus type 1.
    Dey AK; David KB; Klasse PJ; Moore JP
    Virology; 2007 Mar; 360(1):199-208. PubMed ID: 17092531
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural characteristics correlate with immune responses induced by HIV envelope glycoprotein vaccines.
    Sharma VA; Kan E; Sun Y; Lian Y; Cisto J; Frasca V; Hilt S; Stamatatos L; Donnelly JJ; Ulmer JB; Barnett SW; Srivastava IK
    Virology; 2006 Aug; 352(1):131-44. PubMed ID: 21894641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques.
    Hessell AJ; Poignard P; Hunter M; Hangartner L; Tehrani DM; Bleeker WK; Parren PW; Marx PA; Burton DR
    Nat Med; 2009 Aug; 15(8):951-4. PubMed ID: 19525965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A conformational switch in human immunodeficiency virus gp41 revealed by the structures of overlapping epitopes recognized by neutralizing antibodies.
    Pejchal R; Gach JS; Brunel FM; Cardoso RM; Stanfield RL; Dawson PE; Burton DR; Zwick MB; Wilson IA
    J Virol; 2009 Sep; 83(17):8451-62. PubMed ID: 19515770
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection.
    Sather DN; Armann J; Ching LK; Mavrantoni A; Sellhorn G; Caldwell Z; Yu X; Wood B; Self S; Kalams S; Stamatatos L
    J Virol; 2009 Jan; 83(2):757-69. PubMed ID: 18987148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.
    Binley JM; Lybarger EA; Crooks ET; Seaman MS; Gray E; Davis KL; Decker JM; Wycuff D; Harris L; Hawkins N; Wood B; Nathe C; Richman D; Tomaras GD; Bibollet-Ruche F; Robinson JE; Morris L; Shaw GM; Montefiori DC; Mascola JR
    J Virol; 2008 Dec; 82(23):11651-68. PubMed ID: 18815292
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular architecture of native HIV-1 gp120 trimers.
    Liu J; Bartesaghi A; Borgnia MJ; Sapiro G; Subramaniam S
    Nature; 2008 Sep; 455(7209):109-13. PubMed ID: 18668044
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Toward an AIDS vaccine.
    Walker BD; Burton DR
    Science; 2008 May; 320(5877):760-4. PubMed ID: 18467582
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of V3-specific cleavage of recombinant HIV-1 gp120 produced in Chinese hamster ovary cells.
    Du SX; Xu L; Viswanathan S; Whalen RG
    Protein Expr Purif; 2008 Jun; 59(2):223-31. PubMed ID: 18406166
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Focused dampening of antibody response to the immunodominant variable loops by engineered soluble gp140.
    Selvarajah S; Puffer BA; Lee FH; Zhu P; Li Y; Wyatt R; Roux KH; Doms RW; Burton DR
    AIDS Res Hum Retroviruses; 2008 Feb; 24(2):301-14. PubMed ID: 18284327
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.